(Q31423025)

2 July 2017

title

Effectiveness and tolerability of zafirlukast for the treatment of asthma in children (English)

1 reference

2 July 2017

1 reference

1 reference

D S Pearlman

1

1 reference

2 July 2017

K L Lampl

2

1 reference

2 July 2017

P J Dowling

3

1 reference

2 July 2017

C J Miller

4

1 reference

2 July 2017

C M Bonuccelli

5

1 reference

2 July 2017

language of work or name

1 reference

1 June 2000

1 reference

2 July 2017

published in

Clinical Therapeutics

1 reference

2 July 2017

volume

22

1 reference

2 July 2017

issue

6

1 reference

2 July 2017

page(s)

732-747

1 reference

Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Physical growth: National Center for Health Statistics percentiles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990007-9

7 January 2021

10.1016/S0149-2918(00)90007-9

Identifiers

DOI

1 reference

2 July 2017

1 reference